Ben CONFIRMS future Dienogest Natazia investigations. Schliemann was Lich analysis of the results on information from a frozen biopsy taken with the index L TRUSguidance Commission prior to radiotherapy is based. The use of frozen biopsies can k Not on the heterogeneity t and respond to intraprostatic complete genome in each prostate. Suggest, however, clinical data, that mission is the dominant L As a biopsy in this study, the h Most frequent site of post-radiotherapy recurrence and contains 80% of the clone Lt t Fatal if patients with cancer of the prostate cancer. The validation of our findings in a surgical cohort have been demonstrated, but further studies, the cohorts of radiotherapy intermedi Ben rem risk Methods to recognize further validate the Prognosef Ability / pr Diktiv both star and HSD17B2 in localized disease. Conclusion We demonstrate for the first time that allelic losses are of StAR and HSD17B2 loci with significant prognostic factors for biochemical recurrence after 5 years without undergoing caching in patients at risk for prostate IGRT and validate that result in a surgical cohort. With the observed survival advantage to the addition of ADT for IGRT and drugs that should be connected to the n HIGHEST axis androgen we that star, HSD17B2, and other genes point in this axis, are investigated by DNA, RNA and protein levels in pr Clinical and clinical studies as potential determinants of the response to treatment in localized disease. Acknowledgments We thank C. Sanders, N. Schultze for valuable comments on the negotiations on the portal CBIO MSKCC validation for our work. This work was supported by the Ontario Institute for Cancer Research through funding from the Government of Ontario, Canada Foundation for Innovation, the Research Fund of Ontario, and IBM made available. Persons were from the Canada Research Chair, the full article This research was supported, but keep in mind that many of the studies examined the previous definition used. Until recently, mCRPC considered resistant to chemotherapy and the treatment was as a palliative. Agents have been studied in phase II trials, which is usually a lack of focus prime Rer endpoint specific and often were not statistically significant groups acquired participants.4 In a review of 26 studies 1987-1991 VER Published, the treatment with single agent chemotherapy with very low rates of clinical response.5 brought in the 1990s, a controlled study in conjunction The randomized showed that mitoxantrone plus prednisone in low doses a gr Ere improvements provided in the Lebensqualit t as prednisone alone.6 Few time later ter, created a second study that examined hydrocortisone, with or without mitoxantrone Lebensqualit benefit of t as a valid clinical trial end point.7 Although none of these studies showed an improvement in the MK-8669 survival period, the results were viewed as a milestone in the treatment of mCRPC. Subsequently End, the combination of mitoxantrone and prednisone in low doses to the standard of palliative care. Only five years later Ter, that two large randomized Phase III e, the landscape for mCRPC chemotherapy VER Changed. Phase III trial Southwest Oncology 9916 showed eight and nine times the TAX 327 study, a significant survival advantage of 2 months for.